Egypt’s President Abdel Fatah Al-Sisi reviewed, on Tuesday, the progress of the manufacture and assembly of plasma derivatives project, conducted in cooperation with the Spanish medical company, Grifols.
Presidency Spokesperson Bassam Rady said that President Al-Sisi met with Grifols’ Chairperson Victor Grifols.
During the meeting, the President directed for the project’s speedy implementation, which represents a huge addition to a series of national projects aimed at providing citizens with an advanced health system. It also aims to localise the technology for manufacturing and assembling plasma in Egypt.
President Al-Sisi also called for the project to be established in accordance with the highest international standards. He asserted the importance of transferring the company’s experience to manage medical centres, and to possess the capacity in this vital field, which has a direct impact on the health and safety of Egyptian citizens.
The President also ordered for plasma derivatives collection centres to be established in Egypt. This would also see an effective and accurate mechanism set up in cooperation with the Spanish company, to ensure the reliability of their performance. He noted that this project is of the highest priority at the state level.
Meanwhile, the Grifols’ officials expressed their honour at meeting the President, and welcomed the cooperation with Egypt in collecting and manufacturing plasma derivatives. They also welcomed the collaboration in transferring expertise, and localising the medical technology, as well as developing research centres.
This forms part of the Egyptian strategy to cooperate with foreign partners to establish new projects with high efficiency.
Grifols is a Spanish multinational pharmaceutical and chemical manufacturer. The company is a European leader in producing blood plasma-based products, in addition to supplying medical devices, instruments, and reagents for clinical testing laboratories.
The company has reached a strategic agreement to develop Egypt’s local plasma-derived therapies market through the opening of 20 plasma centres, and the construction of production facilities in Egypt. Among these facilities are a plasma fractionation plant and protein purification plants.
The agreement is a unique collaborative opportunity that will strengthen Egypt’s healthcare system and self-sufficiency, while reinforcing Grifols’ international expansion in the Middle East and Africa.
